drug
oxybutynin chloride
Marketedupdated 3mo agoby KVK-Tech Inc
Approvedcommunity read0 votes
all catalysts(0)
nothing on the calendar yet
Trials studying oxybutynin chloride
- N/AOxybutynin ER to Promote Early Continence Recovery After Robotic Prostatectomy: A Randomized Controlled Trial
- phase3Efficacy and Tolerability of DITROPAN XL (Oxybutynin Chloride) Versus DETROL LA (Tolterodine Tartrate) in Treatment of Overactive Bladder
- phase4Clinical Study of Solifenacin Succinate in Patients With Bladder Symptoms Due to Spinal Cord Injury or Multiple Sclerosis
- phase1Food Study of Oxybutynin Chloride ER Tablets 10 mg and Ditropan XL® Tablets 10 mg
- phase1Fasting Study of Oxybutynin Chloride Extended-release Tablets 5 mg and Ditropan XL® Tablets 5 mg
- phase1Fasting Study of Oxybutynin Chloride ER Tablets 10 mg and Ditropan XL® Tablets 10 mg
- phase1Fasting Study of Oxybutynin Chloride Extended-Release Tablets 15 mg and Ditropan XL® Tablets 15 mg
- phase1Food Study of Oxybutynin Chloride Extended-release Tablets 5 mg and Ditropan XL® Tablets 5 mg
Patent cliff
source: FDA Orange Bookfirst barrier falls
Nov 6, 2029
~3.2 years out
Earliest of all listed patents + FDA exclusivities. Generic / biosimilar entry typically only becomes possible AFTER both patent and exclusivity barriers expire.
patents (3)
- Mar 26, 2031method-of-use (U-1644)US 89203924.6y
- Nov 6, 2029formulationUS 104491733.2y
- Nov 6, 2029method-of-use (U-1644)US 92593883.2y
News(0)
no news has mentioned this drug yet
Data sources
last refreshed 48m ago
Found something off?
comments(0)
5-min edit window · permanent after that